Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma

NCT03661554 is registered in ClinicalTrials.gov with The Pregene (ShenZhen) Biotechnology Company, Ltd. as lead sponsor.

NCT NCT03661554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03661554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma
Lead sponsor
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2018
Completion date
November 30, 2018
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory multiple myeloma